Join
Live feed
·
PRReleasevia Quantisnow
Celldex Therapeutics Inc. logo

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
CLDX· Celldex Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CLDX (Celldex Therapeutics Inc.) and more on Quantisnow.